Advancements in Low-Risk MDS Treatments

In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.

You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA. They discuss important considerations for physicians when treating LR-MDS, providing valuable insights into some of the common pitfalls in clinical practice which may lead to suboptimal responses in patients.

The post Novel developments in lower-risk MDS & important practical considerations when treating patients appeared first on VJHemOnc.